Ariel R Topletz-Erickson,JoAl G Mayor,Hsu-Tai Liu et al.
Ariel R Topletz-Erickson et al.
Background and objective: Tucatinib is a selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved to treat metastatic HER2-positive breast and colorectal cancers. The Internation...
Clinical Trial
Drugs in R&D. 2023 Dec;23(4):411-419. DOI:10.1007/s40268-023-00440-8 2023
Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways [0.03%]
探寻心衰患者使用沙库巴曲缬沙坦治疗后NT-proBNP和sST2变化的动力学：不同治疗途径的线索
Massimo Mapelli,Irene Mattavelli,Elisabetta Salvioni et al.
Massimo Mapelli et al.
Background and objective: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble interleukin 1 receptor-like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severi...
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System [0.03%]
FDA不良事件报告系统中帕菲司替尼药物警戒研究的安全性分析
Dehua Zhao,Xiaoqing Long,Jiping Zhou et al.
Dehua Zhao et al.
Background: Infigratinib is a fibroblast growth factor receptor (FGFR)-specifc tyrosine kinase inhibitor indicated for the treatment of patients with previously treated, unresectable, locally advanced or metastatic cholan...
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis [0.03%]
奥扎莫德治疗复发型多发性硬化症关键三期试验结果：与活性对照组相比，具有效应优势且安全性相当
Martin Vališ,Anat Achiron,Hans Peter Hartung et al.
Martin Vališ et al.
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved med...
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab [0.03%]
阿达木单抗仿制药(AQVHV)的理化和功能性特征与原研药相似性的验证研究
Yijia Jiang,Taruna Arora,Scott Klakamp et al.
Yijia Jiang et al.
Background: Adalimumab-aqvh/CHS-1420 (YUSIMRYTM) (hereafter referred to as adalimumab-aqvh) was recently approved by the US Food and Drug Administration as a biosimilar for adalimumab. ...
Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature [0.03%]
环孢素、他克莫司、西罗莫司或依维莫司引起的震颤：文献综述
Aparna Wagle Shukla,Caroline Lunny,Omar Mahboob et al.
Aparna Wagle Shukla et al.
Calcineurin inhibitors such as cyclosporine and tacrolimus are immunosuppressant drugs that are known to induce tremors. Non-calcineurin inhibitors such as sirolimus and everolimus have also reportedly been accompanied by tremors, albeit le...
In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period [0.03%]
盐水和葡萄糖输液溶液中SB12（依库珠单抗，舒利兹生物仿制药）的延长储存期后的稀释药液在使用过程中的稳定性研究
Minji Tak,Hawon Jeong,Jihoon Yun et al.
Minji Tak et al.
Introduction: SB12 is a biosimilar to eculizumab reference product [SolirisTM (Soliris is a trademark of Alexion Pharmaceuticals, Inc.)] that acts as a C5 complement protein inhibitor. The infusion stability of in-use (di...
Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis [0.03%]
扩张型心肌病的药物治疗疗效比较：系统评价和网状meta分析
Xinyu Tong,Lijuan Shen,Xiaomin Zhou et al.
Xinyu Tong et al.
Background and objective: At present, the therapies of dilated cardiomyopathy concentrated on the symptoms of heart failure and related complications. The study is to evaluate the clinical efficacy of a combination of var...
Risk of Hyponatremia after Tramadol/Acetaminophen Single-Pill Combination Therapy: A Real-World Study Based on the OMOP-CDM Database [0.03%]
基于OMOP-CDM数据库曲马多/对乙酰氨基酚复方制剂导致低钠血症的风险：一项真实世界研究
Yu Jeong Lee,Jinmi Kim,Youngmi Han et al.
Yu Jeong Lee et al.
Background and objective: Tramadol has been reported to cause hyponatremia but the evidence is conflicting. The risk of hyponatremia resulting from combination oral tramadol/acetaminophen (TA) therapy is thus unknown. Thi...
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab [0.03%]
贝伐珠单抗仿制药BAT1706与原研药的理化特性及功能相似性评估
Di Cao,Chunping Deng,Guangying Wang et al.
Di Cao et al.
Background: BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehens...